Novartis Foundation Leprosy Elimination Initiative

The Novartis Foundation is convening experts from the global health and anti-leprosy community to discuss the current state of leprosy treatment and care, and how best to move forward together in the mission to finally eliminate leprosy. This two-day dialogue event is being held in Brasilia, Brazil and is co-hosted by the Novartis Foundation, the Nippon Foundation and Coordenação Geral de Hanseníase e Doenças em Eliminação in the Ministry of Health, Brazil.

Content from this campaign

Health & Healthcare

Novartis Foundation and Microsoft Partner to Develop AI-Enabled Digital Health Tool for Early Leprosy Detection
The Novartis Foundation and Microsoft are partnering to develop an Artificial Intelligence (AI)-enabled Digital Health tool and a Leprosy Intelligent Image Atlas to aid in the early detection of leprosy. Over 200,000 people are diagnosed with leprosy every year. Brazil, India, and Indonesia account for about 80% of new cases. If untreated, patients are left with lifelong disabilities and are often stigmatized in their societies.

Health & Healthcare

New Global Partnership for Zero Leprosy Launches to Accelerate Progress Toward a World Without Leprosy
Ahead of World Leprosy Day on Sunday 28 January 2018, several leading leprosy groups have joined forces to launch a Global Partnership for Zero Leprosy to accelerate progress towards a world without leprosy, also known as Hansen’s disease.

Health & Healthcare

Novartis Foundation and Partners Call for a Global Effort to Make Leprosy History
The Novartis Foundation and its partners published two articles that call for a global effort to make leprosy history. The reviews have been published in the Lancet Infectious Diseases, a leading journal in infectious diseases.The two articles set out an action-oriented strategy for achieving the global goal of zero leprosy transmission.

Health & Healthcare

Novartis Foundation and Fiocruz Convene Global Experts on Strategies for Leprosy Detection
Together with the Oswaldo Cruz Foundation (Fiocruz), a premier research institution in Brazil focused on public health, the Novartis Foundation is co-hosting an expert meeting entitled ‘Strategies to detect and interrupt the global transmission of leprosy’ in Rio de Janeiro, Brazil.

Health & Healthcare

World Leprosy Day: 4 Stories That Show the Ongoing Impact of Leprosy
On World Leprosy Day, as part of the Novartis Foundation’s effort to document the impact of leprosy on patients, their families and communities – as well as our work to stop it – we have added four new entries to our visual story-telling platform, called Global Health Stories.

Health & Healthcare

Novartis Foundation Showcases Progress In Leprosy Elimination Programs
The Novartis Foundation and its partners will highlight progress in efforts toward accelerating the elimination of leprosy at the 19th International Leprosy Congress (ILC) held in Beijing, China from September 18 – 21, 2016. Updates in 11 abstracts on four Novartis Foundation-supported leprosy initiatives in low- and middle-income countries will be showcased in scientific sessions.

Health & Healthcare

Novartis Foundation Commemorates World Leprosy Day with its Continued Efforts to go the Last Mile Toward Elimination
On World Leprosy Day 2016, the Novartis Foundation calls for a greater global commitment to the fight against leprosy to support efforts towards zero transmission of the disease and to reduce stigma. The Novartis Foundation continues to work with partners around the world on early detection and treatment of leprosy, proactive surveillance, the development of diagnostic tools, and contact tracing with preventative treatment.

Health & Healthcare

Novartis Continues Commitment to go the Last Mile in Effort to Eliminate Leprosy
Novartis has renewed its pledge with the World Health Organization (WHO) to work to end leprosy by extending its donation of multidrug therapy (MDT) medicines to treat leprosy through the year 2020. This five-year agreement includes treatments worth more than USD 40 million and up to USD 2.5 million to support the WHO in handling the donation and logistics. Overall it is expected that the program will reach an estimated 1.3 million patients during the next five years. This is part of the company’s commitment in 2012 to the London Declaration on Neglected Tropical Diseases.

Health & Healthcare

Novartis Foundation Leprosy Elimination Dialogue Event Press Release
Novartis logo

More from Novartis

  1. Novartis US Foundation commits $25M to improve health equity by reducing health disparities in the US
    Building on $10M+ commitments to date, US Foundation is providing up to an additional $15M due to emergence of COVID-19 pandemic and elevated focus on...

  2. Novartis US Foundation
    Initiatives summarizing efforts from the Novartis US Foundation.

  3. Novartis COVID-19 Trials
    Novartis clinical trial efforts in COVID-19 R&D.

  4. Novartis US Foundation COVID-19 Response
    In response to the COVID-19 pandemic in the US, the Novartis US Foundation established a Response Fund, which will provide USD 5 million over a one...

  5. Novartis – science based innovation for better patient outcomes
    Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

  6. Novartis Foundation Leprosy Elimination Initiative
    The Novartis Foundation is convening experts from the global health and anti-leprosy community to discuss the current state of leprosy treatment and...

  7. Novartis Access: Medicines to treat chronic diseases in lower-income countries
    Novartis recently announced the launch of the Novartis Access Portfolio, a first-of-its-kind portfolio approach in healthcare industry, aiming to...

  8. The Novartis Malaria Initiative
    For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity...